Although berzosertib as a standalone treatment appears promising [7, 29–33], combination with radiation treatment may potentiate response rates due to the common dependance of HNSCC on ATR as a damage response mechanism [2]. Here, ATR is linked to head and neck squamous cell carcinoma.